'Above all do no harm: ' Horizons in pediatric oncology

Steven D Weitman, N. J. Winick, B. A. Kamen

Research output: Contribution to journalArticle

Abstract

The articles selected in this review highlight some advances in the use of the 'old standards' methotrexate and 6-mercaptopurine for the treatment of children with acute lymphoblastic leukemia, especially the laboratory studies, which may allow a 'pharmacologic phenotyping' to identify children most likely to relapse. In addition, we review the use of 'newer' drugs (epipodophyllotoxins), which may be effective but are also associated with high morbidity (ie, secondary acute myeloid leukemia). As a second issue, 'dose intensity' and the use of high-dose chemotherapy followed by bone marrow transplantation will be challenged, especially in light of peripheral stem cell harvest and the use of growth factors.

Original languageEnglish (US)
Pages (from-to)219-223
Number of pages5
JournalCurrent Opinion in Pediatrics
Volume6
Issue number2
StatePublished - 1994
Externally publishedYes

Fingerprint

Drug Utilization Review
Podophyllotoxin
Pediatrics
6-Mercaptopurine
Bone Marrow Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Methotrexate
Intercellular Signaling Peptides and Proteins
Morbidity
Recurrence
Drug Therapy
Therapeutics
Peripheral Blood Stem Cells

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Weitman, S. D., Winick, N. J., & Kamen, B. A. (1994). 'Above all do no harm: ' Horizons in pediatric oncology. Current Opinion in Pediatrics, 6(2), 219-223.

'Above all do no harm : ' Horizons in pediatric oncology. / Weitman, Steven D; Winick, N. J.; Kamen, B. A.

In: Current Opinion in Pediatrics, Vol. 6, No. 2, 1994, p. 219-223.

Research output: Contribution to journalArticle

Weitman, SD, Winick, NJ & Kamen, BA 1994, ''Above all do no harm: ' Horizons in pediatric oncology', Current Opinion in Pediatrics, vol. 6, no. 2, pp. 219-223.
Weitman, Steven D ; Winick, N. J. ; Kamen, B. A. / 'Above all do no harm : ' Horizons in pediatric oncology. In: Current Opinion in Pediatrics. 1994 ; Vol. 6, No. 2. pp. 219-223.
@article{ae361ffedbfa4e8285984c4ec88afed2,
title = "'Above all do no harm: ' Horizons in pediatric oncology",
abstract = "The articles selected in this review highlight some advances in the use of the 'old standards' methotrexate and 6-mercaptopurine for the treatment of children with acute lymphoblastic leukemia, especially the laboratory studies, which may allow a 'pharmacologic phenotyping' to identify children most likely to relapse. In addition, we review the use of 'newer' drugs (epipodophyllotoxins), which may be effective but are also associated with high morbidity (ie, secondary acute myeloid leukemia). As a second issue, 'dose intensity' and the use of high-dose chemotherapy followed by bone marrow transplantation will be challenged, especially in light of peripheral stem cell harvest and the use of growth factors.",
author = "Weitman, {Steven D} and Winick, {N. J.} and Kamen, {B. A.}",
year = "1994",
language = "English (US)",
volume = "6",
pages = "219--223",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - 'Above all do no harm

T2 - ' Horizons in pediatric oncology

AU - Weitman, Steven D

AU - Winick, N. J.

AU - Kamen, B. A.

PY - 1994

Y1 - 1994

N2 - The articles selected in this review highlight some advances in the use of the 'old standards' methotrexate and 6-mercaptopurine for the treatment of children with acute lymphoblastic leukemia, especially the laboratory studies, which may allow a 'pharmacologic phenotyping' to identify children most likely to relapse. In addition, we review the use of 'newer' drugs (epipodophyllotoxins), which may be effective but are also associated with high morbidity (ie, secondary acute myeloid leukemia). As a second issue, 'dose intensity' and the use of high-dose chemotherapy followed by bone marrow transplantation will be challenged, especially in light of peripheral stem cell harvest and the use of growth factors.

AB - The articles selected in this review highlight some advances in the use of the 'old standards' methotrexate and 6-mercaptopurine for the treatment of children with acute lymphoblastic leukemia, especially the laboratory studies, which may allow a 'pharmacologic phenotyping' to identify children most likely to relapse. In addition, we review the use of 'newer' drugs (epipodophyllotoxins), which may be effective but are also associated with high morbidity (ie, secondary acute myeloid leukemia). As a second issue, 'dose intensity' and the use of high-dose chemotherapy followed by bone marrow transplantation will be challenged, especially in light of peripheral stem cell harvest and the use of growth factors.

UR - http://www.scopus.com/inward/record.url?scp=0028206163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028206163&partnerID=8YFLogxK

M3 - Article

C2 - 8032404

AN - SCOPUS:0028206163

VL - 6

SP - 219

EP - 223

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 2

ER -